20th International Myeloma Society Annual Meeting, Athens [27-30/09/2023]

The 20^th International Myeloma Society (IMS) Annual Meeting will be held in Athens from Wednesday, 27 to Saturday, 30 September 2023.

This event is the globe’s top scientific gathering for multiple myeloma, with over 3,000 delegates working on the disease worldwide (doctors, biologists, basic science researchers, and nurses) registered to participate. The above number is the highest ever recorded for an IMS Annual Meeting. It is important to note that IMS is the main global organization for researching, treating, and informing patients and their families about multiple myeloma.

Greece, through the Plasma Cells Dyscrasias Unit of the Department of Therapeutics of the NKUA’s School of Medicine (Alexandra General Hospital, Director of the Department: Professor Thanos Dimopoulos), actively participates in IMS and holds an important position among the countries with a contribution to the research and treatment of multiple myeloma. In many instances, new treatments for multiple myeloma have been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Greek National Organization for Medicines (EOF), following clinical studies conducted with the participation of the Department of Therapeutics of the NKUA’s School of Medicine.

Accordingly, faculty members from the NKUA’s Department of Therapeutics, namely Professors Thanos Dimopoulos, Evangelos Terpos, and Efstathios Kastritis, together with Eirini Katodritou, Director of the Department of Haematology at the Theagenion Cancer Hospital of Thessaloniki, are members of the Organizing Committee of the 20^th IMS Annual Meeting.

The conference will address every aspect of multiple myeloma, including diagnosis, treatment, the implications of the disease, and the most recent clinical studies. There will also be a special reference to immunotherapy with modified lymphocytes (CAR-T cells) and bispecific antibodies (BiTEs), which, in combination with many innovative medicines, create the conditions for long-term survival and, possibly, cure of patients.

For the conference’s programme, please follow the link below: https://imsannual2023.eventscribe.net/agenda.asp?BCFO=&pfp=Browse%20by%20Day&fa=&fb=&fc=&fd=&all=1&mode=&embedded=true